Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs
Introduction
Chronic nonproductive dry cough is a complicating clinical feature in idiopathic pulmonary fibrosis (IPF) [1]. The cough is bothersome and has been described as “dry and nonproductive” or “hacking”, often accompanying a nagging desire to cough constantly, which is not relieved by coughing [2]. In an analysis of 242 patients with IPF, cough was present in 84% of subjects and was an independent predictor of disease progression [3]. Previous studies [4], [5], [6] have investigated the pathogenesis of cough in IPF; however, cough due to IPF is a diagnosis of exclusion after considering other common disorders. Additionally, reports have demonstrated that at least 50% of cough in IPF patients is not secondary to IPF [1], [7]. B.D. Hope-Gill et al. [8] revealed that patients with IPF in whom gastroesophageal reflux disease (GERD), airway hyper-responsiveness, and other confounding influences were excluded showed enhanced cough reflex sensitivity to capsaicin and substance P (SP) compared with healthy subjects, suggesting a functional upregulation of respiratory tract sensory nerves.
Pirfenidone (5 methyl-1-phenyl-2-[1H]-pyridone) is an antifibrotic drug which delays fibrosis in IPF. In a bleomycin-induced lung fibrosis mouse model, pirfenidone showed antifibrotic and anti-inflammatory effects [9]. A phase III trial in Japan showed that pirfenidone caused a significant reduction in the decline of vital capacity and improved progression-free survival [10]. Pirfenidone has been reported to have anti-inflammatory [11], [12] and antioxidant [13], [14] effects, in addition to antifibrotic effects [15], [16], in experimental models. Furthermore, the effects of pirfenidone on bronchial asthma have been investigated recently [17], [18], and although the effects of pirfenidone on airway hyper-responsiveness remain controversial, these data suggest the possibility that pirfenidone may be used for the treatment of acute allergic airway diseases and may reduce or prevent airway remodeling. However, only one study [19] has clarified the inhibitory effects of pirfenidone on cough in patients with IPF, and no reports of the effects of pirfenidone on cough reflex sensitivity have been published.
Here, we investigated the effects of pirfenidone on increased cough reflex sensitivity to inhaled capsaicin accompanied by eosinophilic airway inflammation in actively sensitized guinea pigs with cough reflex sensitivity. We also examined the effects of pirfenidone on cell components, levels of sensory nerve mediators and neuropeptides in the bronchoalveolar lavage fluid (BALF), and neutral endopeptidase (NEP) activity in the tracheal tissue.
Section snippets
Study animals
Male albino Hartley strain guinea pigs weighing 200–220 g were obtained from the Sankyo Laboratory Service (Toyama, Japan) and were quarantined in the Animal Research Center of Kanazawa University. All animal procedures in this study complied with the standards specified in the Guidelines for the Care and Use of Laboratory Animals at the Takara-machi Campus of Kanazawa University.
Study design
Guinea pigs (n = 8 per group) were assigned to the negative control (NC), positive control (PC), low-dose
Effects of pirfenidone on cough reflex sensitivity
The number of coughs induced following 2 min of exposure to aerosolized capsaicin (10−4 M) during the 3-min observation time was significantly (P < 0.01) increased in the PC group compared with the NC group (Fig. 2a). Pirfenidone significantly decreased the cough reflex in the PFD-high group (P < 0.01) compared with the PC group (Fig. 2a). There were no differences in the number of coughs in naïve guinea pigs, regardless of whether pirfenidone was administered (Fig. 2b).
Effects of pirfenidone on BALF cells
The number of total
Discussion
In the present study, we found that pirfenidone suppressed the increase in cough reflex sensitivity to inhaled capsaicin and the increase in PGE2, SP, and LTB4 levels in the BALF in a dose-dependent manner. We also found that pirfenidone repaired the decrease in NEP activity in the tracheal tissue.
Pirfenidone is an antifibrotic drug with anti-inflammatory and antioxidant effects. The 2011 ATS/ERS/JRS/ALAT guidelines [26] give recommendations for the use of pirfenidone only in selected patients,
Support statement
This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology – Japan (No. 23591142).
Statement of interest
None declared.
Acknowledgments
We thank Luis J. Espinosa and Miki Kashiwano (Kanazawa University, Kanazawa, Japan) for their valuable technical advice.
References (33)
Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines
Chest
(2006)Idiopathic pulmonary fibrosis: a nervous cough?
Pulmonary Pharmacology & Therapeutics
(2004)- et al.
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
European Journal of Pharmacology
(2008) - et al.
Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock
European Journal of Pharmacology
(2002) - et al.
Inhibition of experimental acute pulmonary inflammation by pirfenidone
Pulmonary Pharmacology & Therapeutics
(2003) - et al.
Superoxide scavenging activity of pirfenidone-iron complex
Biochemical and Biophysical Research Communications
(2008) - et al.
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma
Pulmonary Pharmacology & Therapeutics
(2007) - et al.
Effects of macrolides on antigen-induced increases in cough reflex sensitivity in guinea pigs
Pulmonary Pharmacology & Therapeutics
(2010) - et al.
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives
Health and Quality of Life Outcomes
(2005) - et al.
Cough predicts prognosis in idiopathic pulmonary fibrosis
Respirology (Carlton, Vic)
(2011)